fungi
speci
includ
haemophilu
influenza
staphylococcu
aureu
aspergillu
fumigatu
pseudomona
aeruginosa
gangel
et
al
infect
common
pathogen
typic
trigger
neutrophil
respons
howev
fail
erad
infect
lead
sustain
releas
oxid
proteas
particularli
neutrophil
elastas
ne
hartl
et
al
painter
et
al
neutrophilbas
inflamm
associ
progress
structur
abnorm
specif
bronchiectasi
air
trap
earli
month
age
mott
et
al
sli
et
al
addit
colon
bacteria
fungi
cf
airway
infect
respiratori
virus
viral
infect
major
caus
pex
pediatr
cf
popul
goffard
et
al
dijkema
et
al
signific
viral
infect
cf
identifi
advanc
molecular
diagnost
technolog
detect
viru
wat
preval
respiratori
virus
cf
pex
vari
billard
et
al
includ
rhinoviru
rv
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
piv
type
metapneumoviru
coronaviru
adenoviru
water
ratjen
flight
jone
earlier
work
suggest
influenza
virus
b
pribbl
et
al
hiatt
et
al
rsv
abman
et
al
armstrong
et
al
major
caus
pex
cf
howev
studi
util
sensit
virolog
method
last
year
comprehens
establish
rv
common
respiratori
viru
detect
cf
airway
burn
et
al
wark
et
al
kiening
et
al
etherington
et
al
dijkema
et
al
stelzerbraid
et
al
despit
numer
studi
virolog
cf
airway
mechanist
link
viru
infect
airway
inflamm
structur
lung
diseas
remain
larg
unknown
investig
interact
diseas
compon
warrant
member
picornavirida
famili
within
enteroviru
genu
rv
featur
posit
sens
singl
strand
rna
genom
kb
length
airway
epithelium
primari
site
rv
infect
replic
vareil
et
al
review
palmenberg
gern
viral
protein
form
nonenvelop
icosahedr
structur
extern
capsid
protein
compris
locat
interfac
capsid
protein
rna
genom
capsid
protein
featur
high
degre
heterogen
consequ
signific
antigen
divers
among
rv
preclud
vaccin
develop
glanvil
johnston
lewisrog
et
al
current
serotyp
rv
classifi
speci
rva
rvb
rvc
within
rva
rvb
strain
cluster
major
minor
rv
group
base
upon
specif
intracellular
adhes
molecul
receptor
lowdens
lipoprotein
receptor
ldlr
respect
palmenberg
recent
cell
receptor
rvc
speci
put
identifi
cadherin
relat
famili
member
whose
express
larg
confin
ciliat
cell
bochkov
et
al
grigg
et
al
palmenberg
rhinoviru
infect
occur
year
round
children
experi
averag
six
eight
episod
per
year
worral
although
common
cold
larg
selflimit
still
pose
burden
activ
product
gener
popul
stein
addit
rv
infect
pronounc
effect
vulner
individu
children
cf
summar
tabl
includ
increas
pex
asner
et
al
sever
respiratori
symptom
burn
et
al
wark
et
al
greater
inflamm
kiening
et
al
reduc
qualiti
life
hospit
prolong
antibiot
treatment
smyth
et
al
preval
symptom
rv
infect
patient
cf
vari
cohort
review
billard
et
al
report
similar
rate
rv
detect
children
without
cf
de
almeida
et
al
esposito
et
al
other
report
signific
correl
diseas
progress
cf
hiatt
et
al
van
ewijk
et
al
featur
age
prefer
rv
serotyp
viral
load
impact
lung
function
assess
sever
studi
suscept
particular
rv
serotyp
children
cf
requir
investig
due
inconsist
observ
de
almeida
et
al
shah
et
al
rv
load
observ
significantli
higher
children
cf
time
compar
healthi
control
children
asthma
time
kiening
et
al
studi
also
illustr
viral
load
neg
correl
pulmonari
function
kiening
et
al
cousin
et
al
observ
rvinduc
pex
children
cf
result
failur
pulmonari
function
recoveri
week
age
prefer
rvassoci
cf
exacerb
also
report
young
children
year
old
stelzerbraid
et
al
howev
sever
studi
detect
higher
frequenc
rv
upper
lower
airway
adult
cf
via
screen
sputum
throat
swab
etherington
et
al
goffard
et
al
adult
cf
viral
associ
pex
shown
wors
lung
function
requir
day
intraven
antibiot
treatment
flight
et
al
goffard
et
al
other
also
report
adult
patient
less
respons
treatment
readmit
subsequ
exacerb
within
shorter
time
frame
etherington
et
al
final
flight
et
al
found
rv
infect
adult
accompani
increas
risk
pex
prolong
antibiot
prescript
higher
respiratori
symptom
score
heighten
level
creactiv
protein
rv
larg
clinic
impact
cf
critic
elucid
viru
alter
host
antivir
inflammatori
respons
pseudostratifi
epithelium
line
surfac
lung
trachea
primari
bronchi
secondari
bronchi
tertiari
bronchi
bronchiol
compos
sever
cell
type
includ
ciliat
cell
basal
cell
secretori
cell
goblet
cell
whitsett
alenghat
clear
inhal
particlespathogen
intraepitheli
goblet
cell
submucos
gland
mucou
cell
secret
mucin
larg
glycoprotein
bind
matter
includ
microb
allow
effect
cough
clearanc
mucociliari
escal
foster
mucin
transport
bronchiol
trachea
via
beat
cilia
express
airway
epitheli
cell
lumin
airway
surfac
et
al
perhap
significantli
viral
pathogen
airway
epithelium
play
crucial
role
innat
immun
suggest
inflammatori
respons
induc
airway
epitheli
cell
give
rise
associ
clinic
symptom
jacob
et
al
rv
disrupt
epitheli
tight
junction
includ
zona
occluden
protein
stimul
product
reactiv
oxygen
speci
ro
viral
replic
unger
et
al
work
util
airway
epitheli
cell
vitro
shown
reduc
express
tight
junction
protein
loss
epitheli
integr
disrupt
extracellular
matrix
subepitheli
fibrosi
induct
proangiogen
molecul
enhanc
angiogenesi
airway
remodel
bossio
et
al
leigh
et
al
bochkov
et
al
tacon
et
al
yeo
jang
looi
et
al
uptak
rv
via
clathrindepend
independ
endocytosi
micropinocytosi
occur
rv
bind
specif
receptor
upon
bind
lowph
environ
uncoat
rv
occur
viru
undergo
conform
chang
loss
protein
capsid
protein
extern
hydrophob
ntermin
facilit
rv
cross
host
cell
membran
jacob
et
al
blaa
fuch
follow
viral
uncoat
membran
ruptur
rv
pathogenassoci
molecular
pattern
pamp
recogn
host
cell
via
interact
pattern
recognit
receptor
prr
includ
toll
like
receptor
tlr
ctype
lectin
receptor
clr
retino
acidinduc
gene
rigi
like
receptor
rlr
nucleotidebind
oligomer
domainlik
receptor
nlr
signal
pathway
induc
tlr
rlr
typic
host
defens
antivir
pathway
well
product
antivir
substanc
name
ifn
bdefensin
proud
et
al
nitric
oxid
sander
et
al
airway
epithelium
also
respond
rv
infect
activ
proinflammatori
signal
pathway
trigger
releas
chemokin
cytokin
includ
granulocytemacropahg
colonystimul
factor
gmcsf
turn
recruit
neutrophil
esoinophil
natur
killer
cell
nk
cell
macrophag
infect
tissu
import
role
innat
immun
respons
induc
rv
infect
product
shown
invers
correl
cold
symptom
score
diseas
sever
doyl
et
al
exert
import
antivir
cytotox
effect
involv
activ
differenti
surviv
recruit
nk
cell
cell
jayaraman
et
al
associ
rv
infect
well
cold
symptom
score
gern
et
al
furthermor
also
associ
neutrophil
infiltr
sputum
gern
et
al
taken
togeth
evid
innat
immun
signal
induc
airway
epithelium
essenti
effect
antivir
respons
howev
mani
chronic
airway
diseas
includ
cf
antivir
respons
defect
due
preexist
genet
defect
normal
function
cf
airway
epithelium
often
disrupt
primari
site
viru
entri
replic
viral
infect
understand
consequ
lack
cftr
function
pathophysiolog
viru
infect
critic
effect
diseas
manag
relev
vitro
experiment
studi
investig
rv
infect
cf
epithelium
summar
tabl
studi
perform
date
assess
cell
obtain
adult
cf
cohort
signific
diseas
structur
lung
damag
studi
report
similar
level
interferon
product
post
infect
despit
higher
viral
load
detect
chattoraj
et
al
dauletbaev
et
al
studi
cell
pediatr
cf
cohort
may
gener
relev
data
potenti
reveal
new
insight
earli
life
rv
infect
could
exploit
therapeut
also
import
level
proinflammatori
cytokin
produc
cf
epithelium
follow
rv
infect
mani
studi
report
similar
level
type
iii
ifn
product
other
report
higher
level
product
depend
viru
strain
infecti
titer
tabl
contradictori
observ
may
due
part
age
patient
involv
diseas
sever
rv
strain
dose
length
infect
studi
date
includ
focus
specif
host
respons
target
gene
protein
level
might
reflect
global
innat
immun
chang
rv
infect
translat
target
approach
would
identif
singl
molecul
address
singl
pathway
ultim
target
one
downstream
effect
product
singl
cytokin
howev
know
interact
rv
airway
multifacet
altern
approach
address
complex
need
date
studi
perform
focus
potenti
treatment
rv
infect
cf
individu
rv
continu
preval
detect
viru
individu
includ
cf
airway
addit
evid
need
specifi
connect
exist
factor
lack
cftr
airway
inflamm
molecular
intermedi
cellular
signal
pathway
common
antiinflammatori
includ
oral
corticosteroid
highdos
ibuprofen
unsuit
treatment
infant
preschool
children
due
longterm
side
effect
lai
et
al
fennel
et
al
azithromycin
may
interest
antivir
properti
specif
reduc
rv
replic
via
amplif
ifn
pathwaymedi
antivir
respons
et
al
nevertheless
clinic
studi
necessari
elucid
clinic
impact
azithromycin
rvinduc
pex
patient
cf
vaccin
import
part
cf
clinic
care
howev
vaccin
develop
rv
rather
challeng
due
wide
rang
antigen
divers
serotyp
rv
across
three
differ
strain
technic
difficulti
produc
suffici
amount
antigen
multipl
rv
serotyp
use
anim
model
review
del
vecchio
et
al
also
remain
challeng
result
develop
longlast
rv
vaccin
success
compound
lack
suitabl
model
human
fulli
permiss
rv
infect
well
insuffici
clinic
data
identifi
priorit
domin
rv
serotyp
addit
suitabl
anim
model
cf
exhibit
complet
spectrum
cf
phenotyp
besid
cf
pig
ferret
strictli
limit
research
use
review
rosen
et
al
sinc
vaccin
unavail
approach
explor
healthi
diseas
cohort
cf
earli
approach
turner
et
al
aim
prevent
hrv
bind
receptor
via
administr
inhal
recombin
solubl
tremacamra
although
reduct
symptom
sever
viral
shed
promis
high
cost
dose
regimen
recommend
time
daili
made
translat
therapi
clinic
set
prohibit
turner
et
al
target
viral
replic
perhap
highest
prioriti
past
therapeut
develop
capsidbind
drug
bind
hydrophob
pocket
viral
capsid
review
mckinlay
et
al
pleconaril
pirodavir
discontinu
due
unforeseen
side
effect
drug
efficaci
reformul
pleconaril
vapendavir
complet
clinic
trial
although
result
yet
publish
clinicaltrialsgov
recent
discov
compound
offer
promis
mousnier
et
al
molecul
shown
inhibit
human
nmyristoyltransferas
prevent
viru
assembl
suppress
rv
replic
infect
across
variou
rv
strain
without
induc
cytotox
howev
work
demonstr
use
cell
line
adult
primari
cell
assess
primari
cell
young
children
cf
necessari
outcom
studi
would
inform
whether
compound
exert
similar
efficaci
across
cohort
polymorph
dna
loci
associ
host
variat
gene
express
call
responsereqtl
rhinoviru
infect
previous
report
et
al
altern
role
type
ifn
administr
enhanc
primari
antivir
signal
pathway
innat
immun
also
assess
earli
studi
involv
prophylact
administr
found
demonstr
reduct
number
rvinduc
episod
differ
symptom
sever
durat
farr
et
al
hayden
et
al
monto
et
al
sperber
et
al
multipl
side
effect
high
dose
administr
ifn
includ
nasal
bleed
transient
leukopenia
sore
throat
also
report
sperber
et
al
recent
studi
assess
low
dose
administr
although
antivir
activ
enhanc
aid
reduc
cold
symptom
viral
induc
exacerb
asthma
cohort
et
al
ruuskanen
et
al
also
suggest
shortterm
subcutan
pegyl
combin
oral
ribavirin
treatment
rapidli
decreas
rv
rna
recurr
chronic
rhinoviru
infect
immunocompromis
patient
altern
therapi
thoroughli
assess
cf
cohort
ongo
clinic
trial
comprehens
evalu
efficaci
cftr
potenti
corrector
applic
mutat
specif
patient
improv
infect
inflamm
therapi
would
highli
desir
individu
cf
inde
ivacaftor
found
reduc
sputum
p
aeruginosa
densiti
airway
inflamm
significantli
hisert
et
al
whether
improv
cftr
fold
function
enhanc
antivir
respons
children
cf
warrant
investig
multitarget
drug
design
also
hold
potenti
could
employ
exert
antivir
antiinflamm
effect
understand
host
antivir
inflammatori
respons
differ
cf
airway
particularli
young
children
critic
facilit
develop
new
therapeut
treatment
limit
cf
diseas
progress
current
therapi
direct
rv
mainli
focus
specif
viral
protein
inhibit
viral
cycl
howev
drug
effect
drugresist
viral
strain
current
review
propos
altern
approach
focus
host
cellular
pathway
factor
expedit
novel
therapeut
strategi
investig
cellular
signal
pathway
alter
rv
infect
alter
manipul
new
compound
drug
crucial
new
therapeut
develop
current
field
system
biolog
adopt
highthroughput
technolog
transcriptom
facilit
character
hostpathogen
interact
comprehens
manner
also
aid
understand
develop
repurpos
compound
exert
antivir
properti
rv
infect
cf
patient
know
virus
manipul
host
signal
process
thu
alter
hostpathogen
interact
christiaansen
et
al
evalu
global
chang
gene
express
infect
via
employ
genetranscriptom
could
elucid
crucial
messag
therapeut
target
identif
transcriptom
use
studi
total
rna
output
cell
earli
transcriptom
analys
perform
use
microarray
custom
probe
current
transcriptom
analys
reli
highthroughput
rna
sequenc
captur
global
transcriptom
mortazavi
et
al
techniqu
allow
analysi
molecul
regul
gene
level
illustr
interact
within
cell
complex
hostpathogen
interact
enhanc
diminish
specif
molecul
well
precis
character
specif
target
promis
therapeut
approach
review
cesur
gener
comput
approach
use
organ
manag
data
set
interpret
biolog
infer
includ
network
analysi
innatedb
networkanlayst
cytoscap
pathway
analysi
reactom
kegg
pathway
pantherdb
context
hostvir
interact
transcriptom
analysi
success
appli
identifi
uncharacter
isoform
wildtyp
dengu
infect
host
rna
human
hepatoma
cell
author
demonstr
infect
wildtyp
dengu
viru
elicit
differ
host
respons
compar
infect
vaccin
sensit
strain
highlight
potenti
strainspecif
respons
session
et
al
transcript
profil
blood
specimen
figur
propos
workflow
use
transcriptom
elucid
futur
treatment
cold
viru
infect
cf
frontier
pharmacolog
wwwfrontiersinorg
symptomat
asymptomat
patient
rv
infect
reveal
individu
activ
infect
demonstr
robust
transcript
signatur
immunerel
gene
heinonen
et
al
diseas
set
includ
asthma
allerg
rhiniti
transcriptom
respons
human
respiratori
cell
surrog
rv
infect
poli
c
stimul
potenti
identifi
diseasespecif
signatur
wagen
et
al
therefor
imper
assess
global
transcript
express
investig
hostvir
interact
given
cf
defin
genet
diseas
condit
live
rv
infect
truli
repres
activ
infect
might
involv
modif
host
respons
approach
appli
proteincod
rna
also
provid
insight
critic
noncod
rna
short
noncod
rna
mirna
long
noncod
rna
lncrna
key
regul
modul
gene
express
delpu
et
al
map
gene
complet
network
allow
identif
key
hub
gene
central
gene
high
connect
exert
larg
effect
signal
transduct
molecular
network
analysi
also
allow
enrich
function
modul
identifi
area
group
gene
cooper
work
togeth
perform
specif
biolog
function
could
associ
diseas
set
review
cserm
et
al
exampl
includ
identif
strongli
connect
hub
gene
potenti
antifung
drug
target
candida
albican
altwass
et
al
identif
new
key
gene
type
diabet
safarialighiarloo
et
al
well
certain
cancer
zaman
et
al
jin
et
al
moreov
omic
data
discov
diseas
modul
reveal
substanti
interpati
heterogen
highlight
potenti
import
custom
treatment
condit
numer
algorithm
introduc
identifi
diseas
modul
includ
modulediscover
identifi
rodent
model
nonalcohol
steatohepat
nash
well
sever
form
nonalcohol
fatti
liver
diseas
nafld
vlaic
et
al
maxim
efficaci
treatment
outcom
patient
individu
characterist
includ
genet
profil
need
consid
although
use
biolog
network
analysi
expedit
drug
discoveri
process
timelin
target
identif
clinic
applic
still
lengthi
altern
strategi
explor
drug
repurpos
integr
analysi
diseasegen
profil
pathway
analysi
mine
fda
approv
drug
databas
carri
identifi
correl
common
pathway
certain
compound
molecul
network
level
success
exampl
drug
repurpos
base
transcriptom
analys
includ
identif
topiram
treatment
inflammatori
bowel
diseas
ibd
cimetidin
treatment
lung
adenocarcinoma
sirota
et
al
use
largescal
express
signatur
lee
et
al
also
identifi
ivermectin
trifluridin
astemizol
amlodipin
maprotilin
apomorphin
mometason
nortriptylin
show
signific
antiprolif
activ
glioblastoma
recent
establish
immport
data
repositori
promot
research
dataset
repurpos
bhattacharya
et
al
identif
novel
target
repurpos
drug
target
acceler
current
pauciti
data
cfrelat
rvtherapi
given
impact
cf
lung
diseas
thu
new
intervent
urgent
requir
strategi
repurpos
alreadi
approv
drug
could
advanc
antivir
therapi
reduc
cost
improv
qualiti
life
affect
individu
rv
infect
remain
signific
caus
pulmonari
exacerb
cf
littl
investig
antivir
therapi
cf
especi
young
children
suscept
type
infect
howev
modern
virolog
procedur
omic
technolog
facilit
indepth
studi
gene
molecular
pathway
involv
aberr
cf
antivir
respons
rv
propos
transcriptom
could
leverag
elucid
futur
therapeut
intervent
treatment
rhinoviru
infect
cf
exampl
global
gene
express
profil
bronchial
epitheli
cell
patient
cf
baselin
condit
rv
infect
profil
follow
nextgener
rna
sequenc
figur
sequenc
align
map
alreadi
avail
refer
genom
identifi
differenti
express
gene
preand
postinfect
identifi
gene
could
annot
use
onlin
repositori
librari
investig
enrich
function
biolog
pathway
moreov
network
subnetwork
construct
map
identifi
gene
explor
relationship
use
curat
proteinprotein
interact
databas
therapeut
opportun
also
identifi
explor
proteinprotein
interact
proteintranscript
factor
proteindrug
interact
well
chemic
interact
databas
final
monolay
cell
cultur
previous
found
suscept
rv
infect
bochkov
et
al
repres
oversimplifi
model
multicellular
interact
epitheli
ciliat
cell
goblet
cell
immun
cell
dendrit
cell
neutrophil
inde
function
valid
util
human
vitro
airway
model
boda
et
al
need
elucid
hostpathogen
interact
emerg
singl
cell
transcriptom
could
use
compliment
airway
model
acceler
progress
new
era
scientif
research
overal
advanc
promis
tool
aid
expedit
new
therapeut
intervent
sphere
kml
lg
ak
conceptu
content
manuscript
kml
wrote
first
draft
manuscript
kml
lg
tl
ss
ak
contribut
draft
edit
manuscript
waerp
ausrec
arest
cf
approv
final
submiss
manuscript
